FindTrial
Sign In

IC14

BIOLOGICAL8 trials

Sponsors

University of Washington, Implicit Bioscience, QuantumLeap Healthcare Collaborative

Conditions

ACMARVCAcute Respiratory Distress SyndromeAmyotrophic Lateral SclerosisArrhythmogenic CardiomyopathyArrhythmogenic Left Ventricular CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy 1Arrhythmogenic Right Ventricular Dysplasia

Phase 1

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
CompletedNCT03487263
Implicit BioscienceAmyotrophic Lateral Sclerosis, Motor Neuron Disease
Start: 2017-10-01End: 2018-12-30Updated: 2025-08-20
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
SuspendedNCT06275893
Implicit BioscienceACM, Arrhythmogenic Cardiomyopathy, Arrhythmogenic Left Ventricular Cardiomyopathy +4
Start: 2024-03-29End: 2026-06-01Target: 5Updated: 2026-03-27

Phase 2

IC14 Antibodies to Treat Individuals With Acute Lung Injury
TerminatedNCT00233207
University of WashingtonLung Diseases, Respiratory Distress Syndrome, Adult
Start: 2005-09-30End: 2007-06-30Updated: 2017-05-16
A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
WithdrawnNCT03017547
Implicit BioscienceAcute Respiratory Distress Syndrome
Start: 2019-06-30End: 2020-06-30Updated: 2025-08-20
IC14 for Treatment of Amyotrophic Lateral Sclerosis
WithdrawnNCT03508453
Implicit BioscienceAmyotrophic Lateral Sclerosis, Motor Neuron Disease
Start: 2021-08-15End: 2023-12-15Updated: 2025-08-17
IC14 in Adult Patients With Dengue Fever
WithdrawnNCT03875560
Implicit BioscienceDengue Fever
Start: 2019-05-31End: 2020-06-30Updated: 2019-03-14
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Active, not recruitingNCT04488081
QuantumLeap Healthcare CollaborativeCOVID-19
Start: 2020-07-31End: 2030-07-31Target: 1500Updated: 2026-03-16

Unknown Phase

IC14 for ALS Patients Expanded Access
NCT04309604
Implicit BioscienceAmyotrophic Lateral Sclerosis
Updated: 2025-08-20

Related Papers

Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case Studies.
2026-01-011 citations
Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
2025-10-29
Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial
CHEST Critical Care2024-12-092 citations
Phosphatidylethanol measures in patients with severe <scp>COVID</scp>‐19‐associated respiratory failure identify a subset with alcohol misuse
Alcohol Clinical and Experimental Research2024-11-26
Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.
2023-03-0318 citations
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations
BMJ Open2022-06-0125 citations
Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis
Medicine2021-10-2214 citations